IP Library Granted Patent US 10,172,862
Granted Patent B2
US 10,172,862 · App. 15/947,840 · Granted Jan 8, 2019

Imipridones for gliomas

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,172,862
App. No.
15/947,840
Granted
Jan 8, 2019
Kind
B2
Abstract

Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.

Claims (10)

1. A method of treating cancer in a subject in need thereof, comprising: administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount compound (1)

or a pharmaceutically acceptable salt thereof, wherein the cancer is a midline glioma having a histone H3 K27M mutation.

2. The method according to claim 1 , wherein the midline glioma is selected from the group consisting of a diffuse intrinsic pontine glioma, a diffuse midline glioma, a spinal cord glioma, a thalamic glioma, a brainstem glioma, and a cerebellar glioma.

3. The method according to claim 1 , wherein the midline glioma is not a spinal cord tumor.

4. The method according to claim 1 , wherein the histone H3 K27M mutation in the midline glioma is H3.3 K27M or H3.1 K27M.

5. The method according to claim 1 , wherein the histone H3 K27M mutation in the midline glioma is in one or more histone genes selected from H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, or HIST1H3J.

6. The method according to claim 1 , wherein in cancerous tissue DRD2 is overexpressed, DRD5 is underexpressed, or both.

7. The method according to claim 1 , wherein the subject is a human.

8. The method according to claim 1 , wherein the subject is a domesticated pet.

9. The method according to claim 1 , wherein the subject is a pediatric subject.

Assignments (2)
CONFIRMATORY PATENT ASSIGNMENT Recorded Oct 27, 2025
From: CHIMERIX, INC.; ONCOCEUTICS, INC.
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073333/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2018
From: ALLEN, JOSHUA E.; STOGNIEW, MARTIN; PRABHU, VARUN VIJAY
To: ONCOCEUTICS, INC.
Reel/Frame 047373/0831 →